SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

$FNA
Medical/Dental Instruments
Health Care
Get the next $FNA alert in real time by email
SC 13G/A 1 mvmsc13ga.htm MVM PARTNERS LP FORM SC 13G

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 2)*

 

Paragon 28, Inc.
(Name of Issuer)
 
Common Stock, $0.01 par value per share
(Title of Class of Securities)
 
69913P105
(CUSIP Number)
 
December 31, 2023
(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed.
o Rule 13d-1(b)
o Rule 13d-1(c)
þ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 
 

 

 

CUSIP No. 69913P105 SCHEDULE 13G  

 

 

1

NAME OF REPORTING PERSON OR

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

MVM Partners, LLC

 
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a) o

(b) o

3

SEC USE ONLY

 

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

5

SOLE VOTING POWER (1)

 

10,886,145

6

SHARED VOTING POWER

 

0

7

SOLE DISPOSITIVE POWER

 

10,886,145

8

SHARED DISPOSITIVE POWER

 

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

10,886,145

 
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

o
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

13.2%

 
12

TYPE OF REPORTING PERSON

 

PN

 
         


 

   

 

 

CUSIP No. 69913P105 SCHEDULE 13G  

 

 

1

NAME OF REPORTING PERSON OR

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

MVM V LP

 
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a) o

(b) o

3

SEC USE ONLY

 

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United Kingdom

 

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

6

SHARED VOTING POWER (1)

 

5,325,843

7

SOLE DISPOSITIVE POWER

 

8

SHARED DISPOSITIVE POWER

 

5,325,843

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

5,325,843

 
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

o
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

6.4%

 
12

TYPE OF REPORTING PERSON

 

PN

 
         


 

   

 

 

 

 

CUSIP No. 69913P105 SCHEDULE 13G  

  

 

1

NAME OF REPORTING PERSON OR

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

MVM V (2020) LP

 
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a) o

(b) o

3

SEC USE ONLY

 

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United Kingdom

 

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

6

SHARED VOTING POWER (1)

 

5,350,592

7

SOLE DISPOSITIVE POWER

 

8

SHARED DISPOSITIVE POWER

 

5,350,592

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

5,350,592

 
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

o
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

6.5%

 
12

TYPE OF REPORTING PERSON

 

PN

 
         

 

 

   

 

 

CUSIP No. 69913P105 SCHEDULE 13G  


 

 

1

NAME OF REPORTING PERSON OR

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

MVM GP (No. 5) LP

 
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a) o

(b) o

3

SEC USE ONLY

 

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United Kingdom

 

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

6

SHARED VOTING POWER (1)

 

209,710

7

SOLE DISPOSITIVE POWER

 

8

SHARED DISPOSITIVE POWER

 

209,710

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

209,710

 
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

o
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.3%

 
12

TYPE OF REPORTING PERSON

 

PN

 
         

 

 
 

 

CUSIP No. 69913P105 SCHEDULE 13G  

 

 

Item 1. (a) Name of Issuer:
    Paragon 28, Inc.
     
  (b) Address of Issuer’s Principal Executive Offices:
   

 

8310 South Valley Highway

Suite 3115

Englewood, CO 80112

   
Item 2. (a) - (c) Name of Person Filing; Address of Principal Business Office; and Citizenship
   

 

·         MVM Partners, LLC (“MVM Partners”), a Delaware limited liability company;

·         MVM V LP (“MVM V”), an entity formed under the laws of the United Kingdom;

·         MVM V (2020) LP (“MVM V 2020”), an entity formed under the laws of the United Kingdom; and

·         MVM GP (No. 5) LP (“MVM GP”), an entity formed under the laws of the United Kingdom.

 

The principal business address and principal office of MVM Partners is Old City Hall, 45 School Street, Boston, MA 02108, the principal business address and principal office of MVM V and MVM V 2020 is 38 Wigmore Street, Fourth Floor, Suite 2, London W1U 2RU, United Kingdom and the principal business address and principal office of MVM GP is 50 Lothian Road, Festival Square, Edinburgh, Scotland, EH3 9WJ.

 

     
  (d) Title of Class of Securities: Common Stock
     
  (e) CUSIP Number: 69913P105

 

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
     
  (a) [__] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
  (b) [__] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c)
  (c) [__] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)
  (d) [__] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
  (e) [__] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E)
  (f) [__] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);
  (g) [__] A Parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);
  (h) [__] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
  (i) [__] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
  (j) [__] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

 

Item 4. OWNERSHIP
   
 

(a) Amount Beneficially Owned:

MVM Partners. – 10,886,145

MVM V – 5,325,843

MVM V 2020 – 5,350,592

MVM GP – 209,710

 

 

(b) Percent of Class:

 

MVM Partners. – 13.2%

MVM V – 6.4%

MVM V 2020 – 6.5%

MVM GP – 0.3%

 

 

   

 

   

 

 

 

  (c) Number of Shares to which such person has:

(i) Sole power to vote or direct the vote:

 

MVM Partners. – 10,886,145

MVM V – 0

MVM V 2020 – 0

MVM GP – 0

 

(ii) Shared power to vote or direct the vote:

 

MVM Partners. – 0

MVM V – 5,325,843

MVM V 2020 – 5,350,592

MVM GP – 209,710

 

(iii) Sole power to dispose or to direct the disposition of:

 

MVM Partners. – 10,886,145

MVM V – 0

MVM V 2020 – 0

MVM GP – 0

 

(iv) Shared power to dispose or to direct the disposition of:

 

MVM Partners. – 0

MVM V – 5,325,843

MVM V 2020 – 5,350,592

MVM GP – 209,710

 

The percentages used in this Amendment are calculated based upon on a total of 82,701,207 outstanding shares of Common Stock of the Issuer as reported in the Issuer’s Current Report on Form 10-Q filed on November 8, 2022.

 

 

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
   
 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

 

   
Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
   
  Not applicable
   
Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
   
  Not applicable.
   
Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
   
  Each of the Reporting Persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended.
   
Item 9. NOTICE OF DISSOLUTION OF GROUP.
   
  Not applicable.
   

 

   

 

 

 

Item 10. CERTIFICATIONS.
   
  By signing below the undersigned certify that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing of influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

 
 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 13, 2024 MVM Partners, LLC
   
  By: /s/ Eric Bednarski
  Name: Eric Bednarski
  Title: Vice President
     
  MVM V LP
   By: MVM Partners, LLC, its Fund Manager
  By: /s/ Eric Bednarski
  Name: Eric Bednarski
  Title: Vice President
     
  MVM V (2020) LP
   By: MVM Partners, LLC, its Fund Manager
  By: /s/ Eric Bednarski
  Name: Eric Bednarski
  Title: Vice President
     
  MVM GP (No. 5) LP
   By: MVM Partners, LLC, its Fund Manager
  By: /s/ Eric Bednarski
  Name: Eric Bednarski
  Title: Vice President

 

 

Get the next $FNA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FNA

DatePrice TargetRatingAnalyst
1/29/2025Buy → Hold
Needham
1/29/2025Outperform → Mkt Perform
William Blair
9/29/2023Outperform
William Blair
4/11/2023$23.00Overweight
Stephens
12/14/2022$32.00Buy
B. Riley Securities
3/9/2022$30.00 → $25.00Buy
B of A Securities
3/9/2022$25.00 → $23.00Buy
Canaccord Genuity
2/9/2022$31.00 → $25.00Buy
Needham
More analyst ratings

$FNA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Paragon 28 to Showcase Recent Product Launches at The American College of Foot and Ankle Surgeons Annual Conference

    Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. From March 27-29, Paragon 28 will feature a suite of recently launched products designed to improve foot and ankle patient outcomes and surgeon experience. "We are thrilled to engage with foot and ankle specialists at ACFAS and showcase our latest innovations after an incredibly strong product launch cadence in 2024," said Albert DaCosta, CEO of Paragon 28. "Our progress and innovation in the space is a testament to our mission to continuous

    $FNA
    Medical/Dental Instruments
    Health Care
  • Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act

    Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE:ZBH) ("Zimmer Biomet"). The expiration of the waiting period under the HSR Act represents a significant milestone in the regulatory approval process, satisfying one of the conditions required to complete the proposed merger with Zimmer Biomet. With the HSR Act waiting period expired, the transaction now re

    $FNA
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties
  • Paragon 28 to Feature Several Recent Product Launches at The American Academy of Orthopaedic Surgeons Annual Conference

    Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons ("AAOS"). From March 10th – 14th, Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case management platform designed to streamline surgical planning and execution, integrating AI, data analytics, and 3D modeling​. Provides an intuitive interface for case scheduling, direct communication with engineers, and conversion o

    $FNA
    Medical/Dental Instruments
    Health Care

$FNA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FNA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$FNA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FNA
SEC Filings

See more

$FNA
Leadership Updates

Live Leadership Updates

See more
  • Paragon 28 Appoints Dave Demski to Board of Directors

    Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

    $ATEC
    $FNA
    Medical/Dental Instruments
    Health Care
  • Appointment of Stephen M. Deitsch as new Chief Financial Officer

    OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since September 2020. Steve's leadership was instrumental in Paragon 28's successful IPO on the NYSE in the fall of 2021. Prior to Paragon 28, Steve held CFO r

    $FNA
    Medical/Dental Instruments
    Health Care
  • Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors

    Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board's Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president, Urology and Pelvic Health, for Boston Scientific Corporation and is a member of the Boston Scientific Executive Committee. Ms. Scanlon also is a member of the Boston Scientific Global Council for Inclusion, serving as the executive sp

    $FNA
    Medical/Dental Instruments
    Health Care

$FNA
Financials

Live finance-specific insights

See more
  • Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

    Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basisFourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basisFull-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.  The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over

    $FNA
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties
  • Paragon 28 Reports Third Quarter 2024 Financial Results and Raises 2024 Net Revenue Guidance

    Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a

    $FNA
    Medical/Dental Instruments
    Health Care
  • Paragon 28 To Report Third Quarter 2024 Financial Results on November 12, 2024

    Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The

    $FNA
    Medical/Dental Instruments
    Health Care

$FNA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more